Search

Charles River Laboratories International Inc

Open

SectorGezondheidszorg

272.7 -1.88

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

266.58

Max

279

Belangrijke statistieken

By Trading Economics

Inkomsten

14M

-760K

Verkoop

8.2M

1B

EPS

3.02

Winstmarge

-0.076

Werknemers

18,300

EBITDA

87M

151M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+2.94% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.6B

14B

Vorige openingsprijs

274.58

Vorige sluitingsprijs

272.7

Nieuwssentiment

By Acuity

22%

78%

33 / 339 Rangschikking in Healthcare

Charles River Laboratories International Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 sep 2026, 19:46 UTC

Charles River Laboratories is declining for a fourth consecutive session, influenced by macroeconomic factors and trading below its 20-day moving average.

9 sep 2026, 23:36 UTC

Charles River Laboratories shares are trading slightly higher in after-market hours, despite remaining below their 20-day moving average after recent declines.

8 sep 2026, 20:07 UTC

Charles River Laboratories International Inc shares declined during Tuesday's session, remaining near the lower end of their one-month trading range.

4 sep 2026, 19:16 UTC

Shares of Charles River Laboratories International Inc. are lower today amid notable volatility and broader market concerns about potential Federal Reserve interest rate hikes.

3 sep 2026, 23:01 UTC

Charles River Laboratories is higher in after-market trading, recovering from an initial dip and nearing the upper end of its one-month trading range.

2 sep 2026, 22:02 UTC

Shares of Charles River Laboratories are lower in after-market trading following a volatile session. Broader market dynamics may be influencing the asset's movement.

1 sep 2026, 22:06 UTC

Charles River Laboratories shares rose after-market, continuing to show resilience despite broader market pressure from rising bond yields and inflation expectations.

31 aug 2026, 20:07 UTC

Charles River Laboratories is lower today amid broader market pressures from inflation concerns and potential interest rate hikes following the Jackson Hole Economic Symposium.

28 aug 2026, 23:36 UTC

Charles River Laboratories is advancing in after-market trading, continuing its upward movement since Friday's close amid broader market dynamics. No specific news was identified.

27 aug 2026, 22:01 UTC

Charles River Laboratories shares are higher in after-market hours, reflecting a positive trend despite earlier session volatility. Market factors remain under close observation.

26 aug 2026, 19:16 UTC

Correlated Moves

Charles River Laboratories reports first-quarter revenue of $1.03 billion, missing estimates. Shares are lower amid sector declines and ongoing inflation concerns.

25 aug 2026, 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, maintaining a position near the upper end of their one-month range amid lower crude oil prices.

24 aug 2026, 19:16 UTC

Correlated Moves

Charles River Laboratories is trading roughly flat amid a notable decline in Agilent Technologies. Market focus is on upcoming events, including a Federal Reserve speech.

21 aug 2026, 23:01 UTC

Charles River Laboratories shares declined in after-market trading, amid broader market volatility tied to rising U.S. Treasury yields and inflation concerns.

20 aug 2026, 19:41 UTC

News

Charles River Laboratories partners with Medigen to develop a multivalent enterovirus vaccine, supporting regulatory readiness and non-clinical studies. Shares are trading higher.

19 aug 2026, 23:56 UTC

Charles River Laboratories shares are higher in after-market trading, reaching a notable increase since Wednesday's close and positioning near the upper end of its one-month range.

17 aug 2026, 19:26 UTC

Charles River Laboratories shares are higher today, continuing an upward trend since Friday's close. The stock remains near the top of its one-month trading range.

14 aug 2026, 19:46 UTC

Charles River Laboratories shares are lower amid broader market declines following a drop in U.S. retail sales, indicating potential weakening consumer demand.

13 aug 2026, 19:52 UTC

Correlated Moves

Charles River Laboratories shares are lower today amid rising jobless claims and volatility, reflecting a decline since Wednesday's close.

12 aug 2026, 20:51 UTC

Charles River Laboratories is higher in after-market trading, reflecting positive momentum despite no specific news. Broader market dynamics appear to support this resilience.

11 aug 2026, 19:56 UTC

Charles River Laboratories International Inc. shares are trading higher today, maintaining a position above the 20-day moving average amid routine price movements.

10 aug 2026, 19:16 UTC

News

Charles River Laboratories shares rise as TD Cowen and Mizuho raise price targets to $300 and $264, respectively. The stock shows notable strength since Friday.

7 aug 2026, 19:51 UTC

News

Morgan Stanley raised its price target on Charles River Laboratories to $300, maintaining an Overweight rating as shares move higher since Thursday's close.

6 aug 2026, 22:51 UTC

Shares of Charles River Laboratories International Inc. are lower in after-market trading, continuing a decline from Thursday's close despite being above its 20-day moving average.

5 aug 2026, 23:56 UTC

Charles River Laboratories is higher in after-market hours, recovering from session lows. Broader market sentiment is affected by a disappointing ADP employment report.

4 aug 2026, 19:16 UTC

Correlated Moves

Charles River Laboratories is rising amid positive momentum in the small-cap market, supported by a drop in crude oil prices that eases inflation concerns.

3 aug 2026, 22:06 UTC

Charles River Laboratories shares are slightly higher in after-hours trading, supported by stronger-than-expected manufacturing data showing a rise in the PMI for July.

31 jul 2026, 19:46 UTC

Correlated Moves

Charles River Laboratories reported first-quarter revenue of $1.02 billion and adjusted EPS of $2.06, but shares are lower amid broader market declines.

30 jul 2026, 23:01 UTC

Shares of Charles River Laboratories are higher in after-market trading, reaching a peak above Thursday's close and remaining strong relative to recent trends.

29 jul 2026, 19:18 UTC

Correlated Moves

Charles River Laboratories is lower today amid broader market declines and investor caution ahead of the Federal Reserve's monetary policy announcement.

Peer Vergelijking

Prijswijziging

Charles River Laboratories International Inc Prognose

Koersdoel

By TipRanks

2.94% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 286.455 USD  2.94%

Hoogste 320 USD

Laagste 219 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Charles River Laboratories International Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

10

Buy

2

Hold

0

Sell

Sentiment

By Acuity

33 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat